» Articles » PMID: 34744497

Toward Improvement of Screening Through Mass Spectrometry-based Proteomics: Ovarian Cancer As a Case Study

Overview
Publisher Elsevier
Date 2021 Nov 8
PMID 34744497
Citations 4
Authors
Affiliations
Soon will be listed here.
Abstract

Ovarian cancer is one of the leading causes of cancer related deaths affecting United States women. Early-stage detection of ovarian cancer has been linked to increased survival, however, current screening methods, such as biomarker testing, have proven to be ineffective in doing so. Therefore, further developments are necessary to be able to achieve positive patient prognosis. Ongoing efforts are being made in biomarker discovery towards clinical applications in screening for early-stage ovarian cancer. In this perspective, we discuss and provide examples for several workflows employing mass spectrometry-based proteomics towards protein biomarker discovery and characterization in the context of ovarian cancer; workflows include protein identification and characterization as well as intact protein profiling. We also discuss the opportunities to merge these workflows for a multiplexed approach for biomarkers. Lastly, we provide our insight as to future developments that may serve to enhance biomarker discovery workflows while also considering translational potential.

Citing Articles

Branched-chain amino acid catabolism promotes ovarian cancer cell proliferation via phosphorylation of mTOR.

Lusk H, Haughan M, Bergsten T, Burdette J, Sanchez L bioRxiv. 2024; .

PMID: 39464074 PMC: 11507863. DOI: 10.1101/2024.10.15.618560.


An Integrated Approach to Protein Discovery and Detection From Complex Biofluids.

Luu G, Ge C, Tang Y, Li K, Cologna S, Godwin A Mol Cell Proteomics. 2023; 22(7):100590.

PMID: 37301378 PMC: 10388710. DOI: 10.1016/j.mcpro.2023.100590.


Mass Spectrometry-Based Proteomics of Epithelial Ovarian Cancers: A Clinical Perspective.

Qian L, Sun R, Xue Z, Guo T Mol Cell Proteomics. 2023; 22(7):100578.

PMID: 37209814 PMC: 10388592. DOI: 10.1016/j.mcpro.2023.100578.


Application of Proteomics in Pancreatic Ductal Adenocarcinoma Biomarker Investigations: A Review.

Vellan C, Jayapalan J, Yoong B, Abdul-Aziz A, Mat-Junit S, Subramanian P Int J Mol Sci. 2022; 23(4).

PMID: 35216204 PMC: 8879036. DOI: 10.3390/ijms23042093.

References
1.
Ntai I, Fornelli L, DeHart C, Hutton J, Doubleday P, LeDuc R . Precise characterization of KRAS4b proteoforms in human colorectal cells and tumors reveals mutation/modification cross-talk. Proc Natl Acad Sci U S A. 2018; 115(16):4140-4145. PMC: 5910823. DOI: 10.1073/pnas.1716122115. View

2.
Dochez V, Caillon H, Vaucel E, Dimet J, Winer N, Ducarme G . Biomarkers and algorithms for diagnosis of ovarian cancer: CA125, HE4, RMI and ROMA, a review. J Ovarian Res. 2019; 12(1):28. PMC: 6436208. DOI: 10.1186/s13048-019-0503-7. View

3.
Meys E, Kaijser J, Kruitwagen R, Slangen B, Van Calster B, Aertgeerts B . Subjective assessment versus ultrasound models to diagnose ovarian cancer: A systematic review and meta-analysis. Eur J Cancer. 2016; 58:17-29. DOI: 10.1016/j.ejca.2016.01.007. View

4.
Milani P, Murray D, Barnidge D, Kohlhagen M, Mills J, Merlini G . The utility of MASS-FIX to detect and monitor monoclonal proteins in the clinic. Am J Hematol. 2017; 92(8):772-779. DOI: 10.1002/ajh.24772. View

5.
Albrethsen J, Kaas A, Schonle E, Swift P, Kocova M, Gammeltoft S . Evaluation of a type 1 diabetes serum cohort by SELDI-TOF MS protein profiling. Proteomics Clin Appl. 2012; 3(3):383-93. DOI: 10.1002/prca.200800063. View